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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
“Transitech®” and “improves transit and durably regulates it” pursuant to 
Article 13(5) of Regulation (EC) No 1924/2006
1 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Vivatech submitted for authorisation of a health claim pursuant to Article 13(5) of 
Regulation (EC) No 1924/2006 via the Competent Authority of France, the Panel on Dietetic Products, Nutrition 
and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to 
“Transitech®” and “improves transit and durably regulates it”. The food that is the subject of the health claim is 
“Transitech®”, a food supplement which contains dried parts of Rheum palmatum L. and/or Rheum officinale 
Baillon and/or their hybrids standardised for hydroxyanthracene derivatives, of Althaea officinalis L., of Rosa 
centifolia  L.,  of  Ocimum  basilicum  L.,  of  Coriandrum  sativum  L.,  dried  juice  of  Cynara  scolymus  L. 
standardised for cynarine, Saccharomyces cerevisiae subsp. cerevisiae UVAFERM SC, Bifidobacterium longum 
R0175  and  Lactobacillus  helveticus  R0052.  The  information  provided  was  insufficient  to  establish  that 
Saccharomyces cerevisiae subsp. cerevisiae UVAFERM SC was sufficiently characterised. The Panel considers 
that if in a combination of several microorganisms and/or ingredients one microorganism or ingredient used in 
the  combination  is  not  sufficiently  characterised,  then  the  combination  is  considered  to  be  not  sufficiently 
characterised. The food, “Transitech®”, which is the subject of the claim, is not sufficiently characterised. The 
Panel  concludes  that  a  cause  and  effect  relationship  cannot  be  established  between  the  consumption  of 
“Transitech®” and “improves transit and durably regulates it”. 
© European Food Safety Authority, 2012 
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SUMMARY 
Following an application from Vivatech submitted for authorisation of a health claim pursuant to 
Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of France, the Panel on 
Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific 
substantiation of a health claim related to “Transitech®” and “improves transit and durably regulates 
it”. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. The application includes a request for the protection of proprietary data.  
The food that is the subject of the health claim is “Transitech®”, a food supplement which contains 
per tablet on average 226.8 mg powdered dried underground parts of Rheum palmatum L. and/or 
Rheum officinale Baillon and/or their hybrids standardised for hydroxyanthracene derivatives (2.2 to 
2.76 %, 5 mg/tablet), 38 mg of powdered dried root of Althaea officinalis L., 38 mg of powdered 
dried petals of Rosa centifolia L., 18 mg of powdered dried expressed juice from leaves of Cynara 
scolymus  L.  standardised  for  cynarine  (2.5  %),  18  mg  of  powdered  dried  leaves  of  Ocimum 
basilicum L., 18 mg of powdered dried seeds of Coriandrum sativum L., 1.7x10
8 CFU Saccharomyces 
cerevisiae subsp. cerevisiae UVAFERM SC, and 4x10
6 CFU of each Bifidobacterium longum R0175 
and Lactobacillus helveticus R0052. 
During the validation period and the clock-stop procedure, the applicant was invited to comment on 
the plausibility of an effect on transit time of constituents other than hydroxyanthracene derivatives 
from  Rheum  palmatum  L.  and/or  Rheum  officinale  Baillon  and/or  their  hybrids  contained  in 
“Transitech®”.  The  applicant  indicated  that  Althaea  officinalis  L.,  Rosa  centifolia  L.,  Cynara 
scolymus L., Ocimum basilicum L. and Coriandrum sativum L. are traditionally used to reduce gastro-
intestinal discomfort and are added to support an effect on transit time. The applicant also clarified 
that microorganisms have been added in order to “restore and equilibrate the intestinal microflora”, 
and requested that the evaluation be carried out on the combination of ingredients. 
Upon request from EFSA during the validation period to provide information on the characterisation 
of the strain of Saccharomyces cerevisiae which is used in “Transitech®”, the applicant identified the 
yeast at species level by sequencing analysis of the D2 domain of 26S rDNA. Upon further request 
from EFSA during the clock-stop procedure to provide information on the strain characterisation the 
applicant  stated  that  the  strain  was  identified  as  Saccharomyces  cerevisiae  subsp.  cerevisiae 
UVAFERM  SC  without  providing  additional  experimental  data  or  references  reporting  on  the 
characterisation  of  the  yeast  at  strain  level.  The  Panel  notes  that  the  information  provided  was 
insufficient  to  establish  that  Saccharomyces  cerevisiae  subsp.  cerevisiae  UVAFERM  SC  was 
sufficiently  characterised.  The  Panel  considers  that  Saccharomyces  cerevisiae  subsp.  cerevisiae 
UVAFERM SC is not sufficiently characterised.  
The  Panel  considers  that  if  in  a  combination  of  several  microorganisms  and/or  ingredients  one 
microorganism  or  ingredient  used  in  the  combination  is  not  sufficiently  characterised,  then  the 
combination is considered to be not sufficiently characterised. 
The Panel considers that the food, “Transitech®”, which is the subject of the claim, is not sufficiently 
characterised. 
The  Panel  concludes  that  a  cause  and  effect  relationship  cannot  be  established  between  the 
consumption of “Transitech®” and “improves transit and durably regulates it”. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4 harmonises the provisions that relate to nutrition and health claims , 
and establishes rules governing the Community authorisa tion of health claims made on foods.  As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of  
this Regulation, are authorised in  accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular,  Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of  disease  risk  and  to  children’s  development  and  health)  which  are  based  on  newly  developed 
scientific  evidence,  or  which  include  a  request  for  the  protection  of  proprietary  data,  to  the 
Community list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted  claims  referred  to  in  Article  13(3)  shall  be  submitted  by  the  applicant  to  the  national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
  The application was received on 15/02/2012. 
  The  scope  of  the  application  was  proposed  to  fall  under  a  health  claim  based  on  newly 
developed scientific evidence and includes a request for the protection of proprietary data. 
  On 15/03/2012, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
  The applicant provided the missing information on 21/05/2012. 
  The scientific evaluation procedure started on 11/05/2012. 
  On 24/05/2012, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application, and the 
clock was stopped on 04/06/2012 in compliance with Article 18(3) of Regulation (EC) No 
1924/2006. 
  The  clock  was  restarted  on  19/06/2012.  On  25/06/2012,  EFSA  received  the  requested 
information as submitted by the applicant.  
  On 28/06/2012, the NDA Panel agreed on a list of questions for the applicant to provide 
additional  information  to  accompany  the  application,  and  the  clock  was  stopped  on 
04/07/2012 in compliance with Article 18(3) of Regulation (EC) No 1924/2006. 
  On 16/07/2012, EFSA received the requested information as submitted by the applicant. The 
clock was restarted on 16/07/2012. 
  During  its  meeting  on  12/09/2012,  the  NDA  Panel,  having  evaluated  the  data  submitted, 
adopted an opinion on the scientific substantiation of a health claim related to “Transitech®” 
and “improves transit and durably regulates it”. 
TERMS OF REFERENCE 
EFSA  is  requested  to  evaluate  the  scientific  data  submitted  by  the  applicant  in  accordance  with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
                                                       
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. “Transitech®” and “improves transit and durably regulates it” 
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opinion on the scientific substantiation of a health claim related to “Transitech®” and “improves 
transit and durably regulates it”. 
EFSA DISCLAIMER 
The  present  opinion  does  not  constitute,  and  cannot  be  construed  as,  an  authorisation  for  the 
marketing  of  “Transitech®”,  a  positive  assessment  of  its  safety,  nor  a  decision  on  whether 
“Transitech®” is, or is not, classified as a foodstuff. It should be noted that such an assessment is not 
foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. “Transitech®” and “improves transit and durably regulates it” 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Vivatech, 8 rue Christophe Colomb, 75008 Paris - France. 
The application includes a request for the protection of proprietary data in accordance with Article 21 
of Regulation (EC) No 1924/2006. 
Food/constituent as stated by the applicant 
According  to  the  applicant,  the  food  which  is  the  subject  of  the  claim  is  “Transitech®”. 
“Transitech®”  mainly  contains  rhubarb  (226.8  mg  per  tablet),  mallow  (38  mg  per  tablet)  and 
artichoke (18 mg per tablet) but also contains pale rose, basil, yeasts (Saccharomyces cerevisiae) and 
lactic ferments such as Bifidobacterium longum I-3470 (commercial name: Bifidobacterium Rosell-
175) and Lactobacillus helveticus I-1722 (commercial name: Lactobacillus Rosell-52).  
Health relationship as claimed by the applicant 
According to the applicant, the oral supplement “Transitech ” could play a role in the management 
of perturbed defecation, which is particularly widespread in industrialised countries and occurs in 
many situations of daily life, and could also re-establish a middle-term normal transit. 
Wording of the health claim as proposed by the applicant 
The following wording is proposed by the applicant: “Improves transit and durably regulates it.” 
Specific conditions of use as proposed by the applicant 
According to the applicant, the product is intended for people suffering from occasional constipation 
with a disturbed defecation (2 to 5 stools per week) in the general population, and the recommended 
daily amount is two pills per day, representing 453 mg of rhubarb, including 10 mg of anthracene 
derivatives. The supplementation should be taken over 10 days.  
ASSESSMENT 
1.  Characterisation of the food/constituent 
The food that is the subject of the health claim is “Transitech®”, a food supplement which contains 
per tablet on average 226.8 mg powdered dried underground parts of Rheum palmatum L. and/or 
Rheum officinale Baillon and/or their hybrids standardised for hydroxyanthracene derivatives (2.2 to 
2.76 %, 5 mg/tablet), 38 mg of powdered dried root of Althaea officinalis L., 38 mg of powdered 
dried petals of Rosa centifolia L., 18 mg of powdered dried expressed juice from leaves of Cynara 
scolymus  L.  standardised  for  cynarine  (2.5  %),  18  mg  of  powdered  dried  leaves  of  Ocimum 
basilicum L., 18 mg of powdered dried seeds of Coriandrum sativum L., 1.7x10
8 CFU Saccharomyces 
cerevisiae subsp. cerevisiae UVAFERM SC, and 4x10
6 CFU of each Bifidobacterium longum R0175 
and Lactobacillus helveticus R0052. 
The  applicant  provided  information  on  the  batch-to-batch  variability  with  respect  to  the 
hydroxyanthracene derivative content of the powdered dried underground parts of Rheum palmatum 
L. and/or Rheum officinale Baillon and/or their hybrids, as well as with respect to the cynarine content 
of the dried expressed juice from leaves of Cynara scolymus L. used in “Transitech®”. The applicant 
also provided a certificate of analysis of the hydroxyanthracene derivative and cynarine content of one “Transitech®” and “improves transit and durably regulates it” 
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batch  of  “Transitech®”.  The  applicant  indicated  that  all  ingredients  of  plant  origin  met  the 
requirements set out in the European Pharmacopoeia monographs. 
During the validation period and the clock-stop procedure, the applicant was invited to comment on 
the plausibility of an effect on transit time of constituents other than hydroxyanthracene derivatives 
from  Rheum  palmatum  L.  and/or  Rheum  officinale  Baillon  and/or  their  hybrids  contained  in 
“Transitech®”.  The  applicant  indicated  that  Althaea  officinalis  L.,  Rosa  centifolia  L.,  Cynara 
scolymus L., Ocimum basilicum L. and Coriandrum sativum L. are traditionally used to reduce gastro-
intestinal discomfort, and are added to support an effect on transit time. The applicant also clarified 
that microorganisms have been added in order to “restore and equilibrate the intestinal microflora”, 
and requested that the evaluation be carried out on the combination of ingredients. 
The strain B. longum R0175 is also known as B. longum subsp. longum CNCM I-3470. A culture 
collection number from the Collection Nationale de Cultures de Microorganismes (CNCM I-3470) 
has been provided. The CNCM is a restricted-access non-public collection which has the status of an 
International  Depositary  Authority  under  the  Budapest  Treaty.  Data  on  the  identification  and 
characterisation  of  B. longum  subsp.  longum  CNCM  I-3470  at  species  and  strain  level  were 
considered  in  an  earlier  opinion  of  the  Panel  (EFSA  Panel  on  Dietetic  Products  Nutrition  and 
Allergies (NDA), 2012), where it was concluded that the strain B. longum subsp. longum CNCM 
I-3470 was sufficiently characterised. 
The strain L. helveticus R0052 is also known as L. helveticus CNCM I-1722. A culture collection 
number from the Collection Nationale de Cultures de Microorganismes (CNCM I-1722) has been 
provided. Data on the identification and characterisation of L. helveticus CNCM I-1722 at species and 
strain level were considered in an earlier opinion of the Panel (EFSA Panel on Dietetic Products 
Nutrition and Allergies (NDA), 2012), where it was concluded that the strain L. helveticus CNCM 
I-1722 was sufficiently characterised. 
Upon request from EFSA during the validation period to provide information on the characterisation 
of the strain of Saccharomyces cerevisiae which is used in “Transitech®”, the applicant provided data 
on the identification of the yeast at species level by sequencing analysis of the D2 domain of 26S 
rDNA. Upon further request from EFSA during the clock-stop procedure to provide information on 
the  strain  characterisation,  the  applicant  stated  that  the  strain  was  identified  as  Saccharomyces 
cerevisiae  subsp.  cerevisiae  UVAFERM  SC  without  providing  additional  experimental  data  or 
references  reporting  on  the  characterisation  of the yeast at strain level. The Panel notes that  the 
information provided was insufficient to establish that Saccharomyces cerevisiae subsp. cerevisiae 
UVAFERM SC was sufficiently characterised. The Panel considers that Saccharomyces cerevisiae 
subsp. cerevisiae UVAFERM SC is not sufficiently characterised.  
The  Panel  considers  that  if  in  a  combination  of  several  microorganisms  and/or  ingredients  one 
microorganism  or  ingredient  used  in  the  combination  is  not  sufficiently  characterised,  then  the 
combination is considered to be not sufficiently characterised. 
The Panel considers that the food, “Transitech®”, which is the subject of the claim, is not sufficiently 
characterised. 
The  Panel  concludes  that  a  cause  and  effect  relationship  cannot  be  established  between  the 
consumption of “Transitech®” and “improves transit and durably regulates it”. “Transitech®” and “improves transit and durably regulates it” 
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CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
  The  food,  “Transitech®”,  which  is  the  subject  of  the  health  claim,  is  not  sufficiently 
characterised.  
  A  cause  and  effect  relationship  cannot  be  established  between  the  consumption  of 
“Transitech®” and “improves transit and durably regulates it”. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on “Transitech®” and “improves transit and durably regulates it” pursuant to 
Article  13(5)  of  Regulation  (EC)  No  1924/2006  (Claim  serial  No:  0328_FR).  February  2012. 
Submitted by Vivatech. “Transitech®” and “improves transit and durably regulates it” 
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